|
Market Closed –
|
5-day change | 1st Jan Change | ||
|
23.56 USD |
-0.08% | -2.52% | +22.14% | |
Published on 05/20/2025 at 07:09
This article is reserved for members Unlock the article: REGISTER NOW!
© Reuters – 2025
|
Schrödinger Announces CFO Appointment |
07:09am |
RE |
|
Schrodinger Names Richie Jain Finance Chief |
06:54am |
MT |
|
Schrodinger Inc Says Schrödinger Restructures Operations To Reduce Workforce And Costs – SEC Filing |
May. 19 |
RE |
|
Schrödinger, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-14-2025 01:40 PM |
May. 14 |
|
|
Schrodinger to Present Phase 1 Clinical Data on MALT1 Inhibitor SGR-1505 at EHA Annual Congress and International Conference on Malignant Lymphoma |
May. 14 |
CI |
|
Earnings Flash (SDGR) SCHRODINGER Posts Q1 Loss $-0.82 Per Share, vs. FactSet Est of $-0.82 |
May. 07 |
MT |
|
Earnings Flash (SDGR) SCHRODINGER Reports Q1 Revenue $59.6M, vs. FactSet Est of $54.7M |
May. 07 |
MT |
|
Schrödinger, Inc., Q1 2025 Earnings Call, May 07, 2025 |
May. 07 |
|
|
Schrödinger, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 |
May. 07 |
CI |
|
Schrodinger, Inc. Presents New Preclinical Data at AACR Annual Meeting |
Apr. 28 |
CI |
|
Schrodinger Insider Sold Shares Worth $419,570, According to a Recent SEC Filing |
Apr. 15 |
MT |
|
Schrodinger to Launch Predictive Toxicology Tool in H2 |
Apr. 14 |
MT |
|
Schrödinger’S Statement Regarding FDA Plan To Phase Out Animal Testing Requirement For Monoclonal Antibodies And Other Drugs |
Apr. 14 |
RE |
|
Sector Update: Tech Stocks Gain Late Afternoon |
Apr. 11 |
MT |
|
Sector Update: Tech |
Apr. 11 |
MT |
|
Schrodinger Settles Lawsuit Over Director Compensations; Shares Up |
Apr. 11 |
MT |
|
Schrodinger Settles Lawsuit Over Director Compensations; Shares Up |
Apr. 11 |
MT |
|
Schrödinger, Inc. Elects Bridget Van Kralingen as Member of the Board |
Mar. 10 |
CI |
|
Schrödinger, Inc., Q4 2024 Earnings Call, Feb 26, 2025 |
Feb. 26 |
|
|
Earnings Flash (SDGR) SCHRODINGER Reports Q4 Loss $-0.24 Per Share, vs. FactSet Est of $-0.42 |
Feb. 26 |
MT |
|
Earnings Flash (SDGR) SCHRODINGER Posts Q4 Revenue $88.3M, vs. FactSet Est of $83.2M |
Feb. 26 |
MT |
|
Schrödinger, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024 |
Feb. 26 |
CI |
|
Schrödinger, Inc. Provides Earnings Guidance for the First Quarter and Full Year Ending December 31, 2025 |
Feb. 26 |
CI |
|
Schrodinger Gets Additional Gates Grant to Expand Predictive Toxicology Platform |
Nov. 18 |
MT |
|
Schrödinger, Inc. Receives an Additional $9.5 Million from the Bill & Melinda Gates Foundation |
Nov. 18 |
CI |
SDGR: Dynamic Chart
Schrodinger, Inc. operates a physics-based computational platform that enables the discovery of molecules for drug development and materials applications. The software platform is used by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. The Company operates through two segments: Software and Drug Discovery. The Software segment is focused on selling its software to transform drug discovery across the life sciences industry, as well as to customers in materials science industries. The Drug Discovery segment is focused on building a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have advanced to various stages of discovery and development. The Company’s pipeline of drug discovery programs includes SGR-1505 (MALT1 Inhibitor), SGR-2921 (CDC7 Inhibitor), SGR-3515 (WEE1 Inhibitor). Its software was used by researchers around the world at more than 1,760 academic institutions.
More about the company
Buy
Average target price
31.78USD
Spread / Average Target
+34.88%
Consensus
Quarterly revenue – Rate of surprise
Select your edition
All financial news and data tailored to specific country editions
